Andres Ruiz Briseno
About Andres Ruiz Briseno
Andres Ruiz Briseno is 39 and currently serves as Chief Accounting Officer (CAO) of IDEAYA Biosciences, having been the company’s principal financial officer since December 7, 2023 and principal accounting officer since July 1, 2023; he became CAO on March 1, 2025, with a CFO appointed effective May 2025 to succeed the principal financial officer role . He holds a B.S. in Business Administration (Corporate Financial Management) from San Jose State University and is a Certified Public Accountant licensed in California . Company pay-versus-performance disclosures show cumulative TSR and cash balance trends used in linking compensation to performance; IDEAYA identified “Cash, Cash Equivalents and Marketable Securities” as the most important measure in 2024 .
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Company TSR (Value of $100) | 168.86 | 129.79 | 254.14 | 183.57 |
| Net Loss ($000s) | (49,762) | (58,655) | (112,961) | (274,477) |
| Cash, Cash Equivalents & Marketable Securities ($MM) | 368.1 | 373.1 | 623.6 | 1,082.2 |
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| IDEAYA Biosciences | Chief Accounting Officer (Principal Financial & Accounting Officer) | Mar 2025–present | Elevated to CAO; maintained PFO until CFO appointment effective May 2025 . |
| IDEAYA Biosciences | SVP, Head of Finance & Investor Relations (Principal Financial Officer) | Jul 2023–Feb 2025 | Led finance and IR; served as PFO from Dec 2023 . |
| IDEAYA Biosciences | VP, Head of Business Operations & Investor Relations | Nov 2021–Jun 2023 | Built operations/IR capabilities . |
| IDEAYA Biosciences | Finance roles incl. VP, Finance | Aug 2016–Jul 2021 | Early finance leadership at IDEAYA . |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Neumora Therapeutics | SVP, Finance & Principal Accounting Officer | Jul–Oct 2021 | Led finance and accounting at a biotech peer . |
| Pharmacyclics, Inc. | FP&A roles incl. Associate Director | Prior to 2016 | Oncology biotech finance experience . |
| Theravance, Inc. | Finance roles | Prior to Pharmacyclics | Biopharma finance exposure . |
| PricewaterhouseCoopers | Audit & Assurance (Life sciences & VC focus) | Prior to Theravance | CPA-track audit across LS/VC clients . |
Fixed Compensation
| Year | Base Salary ($) | Target Bonus % | Actual Bonus Paid ($) | All Other Compensation ($) |
|---|---|---|---|---|
| 2023 | 357,500 | 35% | 125,125 | 15,000 |
| 2024 | 382,500 | 35% | 133,875 | 15,600 |
Notes:
- All Other Compensation for Andres includes $1,800 cell phone allowance and $13,800 401(k) employer match (2024) .
Performance Compensation
Annual Cash Incentive – 2024 Structure and Outcome
| Metric Component | Weighting | Target | Actual | Payout ($) | Vesting |
|---|---|---|---|---|---|
| Corporate Objectives (clinical/preclinical 70%; corporate development 30%) | 70% of bonus | 100% of target | 100% achieved (Board/Comp Committee, Feb 2025) | Included in $133,875 | Cash (no vest) |
| Individual Performance Assessment | 30% of bonus | 100% of target | 100% achieved (Feb 2025) | Included in $133,875 | Cash (no vest) |
Program detail:
- Corporate goals spanned IDE397, IDE161, Pol Theta, Werner Helicase and early discovery; corporate development included darovasertib US launch readiness, balance sheet enhancement, investor base, and infrastructure .
- Board determined corporate objectives at 100% of target, also considering IDE849 and IDE034 in-license agreements and balance sheet enhancement .
Equity Awards – Grants and Vesting
| Grant Date | Award Type | Shares | Exercise Price ($/sh) | Grant-Date Fair Value ($) | Vesting | Expiration |
|---|---|---|---|---|---|---|
| 3/1/2024 | Stock Option | 85,000 | 46.22 | 2,823,819 | 25% at 1-year, then 1/48 monthly | 3/1/2034 |
Option exercises and realized value in 2024:
| Name | Shares Exercised (#) | Value Realized ($) |
|---|---|---|
| Andres Ruiz Briseno | — | — |
Equity Ownership & Alignment
| Ownership Measure (as of 3/31/2025) | Count/Amount | % of Outstanding |
|---|---|---|
| Outstanding Shares Beneficially Owned | 25,213 | <1% |
| Shares Exercisable Within 60 Days | 102,867 | <1% |
| Total Beneficial Ownership | 128,080 | <1% |
Outstanding stock options by grant (as of 12/31/2024):
| Vesting Commencement | Exercisable (#) | Unexercisable (#) | Exercise Price ($) | Expiration |
|---|---|---|---|---|
| 11/1/2021 | 46,246 | 13,754 | 22.30 | 11/1/2031 |
| 3/1/2022 | 20,958 | 7,792 | 12.86 | 3/1/2032 |
| 2/24/2023 | 20,360 | 22,140 | 17.04 | 2/24/2033 |
| 6/29/2023 | 7,965 | 14,535 | 23.23 | 6/29/2033 |
| 3/1/2024 | — | 85,000 | 46.22 | 3/1/2034 |
Alignment policies:
- IDEAYA prohibits pledging of company securities and hedging/monetization transactions (including margin accounts, zero-cost collars, forward sale contracts) under its Insider Trading Compliance Policy .
- Clawback: The company maintains a Policy for Recovery of Erroneously Awarded Compensation for executive officers in connection with restatements .
Employment Terms
Severance and change-in-control economics (as of 12/31/2024):
| Scenario | Cash Severance | Target Bonus | Healthcare Coverage | Equity Vesting |
|---|---|---|---|---|
| Involuntary termination without cause or resignation for good reason (outside CIC period) | $286,875 | — | $25,965 | — |
| Involuntary termination without cause or resignation for good reason (within CIC period) | $382,500 | $133,875 | $34,620 | $996,775 (unvested in-the-money options) |
Contractual framework:
- For non-PEO NEOs (including Andres), outside CIC: lump sum equal to 75% of annual base salary plus up to 9 months of healthcare; within CIC (defined as 3 months pre- to 12 months post-close): lump sum equal to 100% of annual base salary and target annual incentive, up to 12 months healthcare, and full acceleration of equity awards (double-trigger) . If options are not assumed/substituted in a change in control, acceleration may occur at close (single-trigger for non-assumed awards) .
- Definitions of “cause,” “good reason,” “change in control,” and “good reason process” are specified; “good reason” includes material salary reduction not broadly applied, relocation increasing commute >75 miles, or material reduction in duties following the cure process .
- No 280G/4999 excise tax gross-ups provided .
Compensation Structure Analysis
- Cash vs equity mix: 2024 compensation included base salary ($382,500), annual cash bonus ($133,875), and a significant option grant fair value ($2,823,819), indicating a heavy equity-at-risk component via options with four-year vesting .
- Performance metrics: Annual bonus tied to corporate goals (clinical/preclinical 70%; corporate development 30%) and individual performance (30% of bonus for NEOs), both assessed at 100% for 2024; the company-selected pay-versus-performance measure was cash/cash equivalents/marketable securities .
- Equity award practices: Options vest 25% at the first anniversary then monthly, aligning retention incentives; the company states awards are not timed around MNPI releases .
Related Party Transactions and Governance
- No related party transactions disclosed involving Andres; the company maintains a related person transaction approval policy overseen by the Audit Committee .
- Compensation Committee membership (independent): Jeffrey L. Stein (Chair), Catherine Mackey, Terry J. Rosen, Wendy L. Yarno; uses a written charter and oversees executive compensation and succession planning .
Investment Implications
- Alignment and retention: Significant unvested options (e.g., 85,000 from 2024 at $46.22) vest monthly after the first anniversary, creating ongoing retention incentives; Andres did not exercise options in 2024, limiting near-term selling pressure signals . Pledging and hedging are prohibited, reducing alignment risk from collateralization or derivatives .
- Change-of-control dynamics: Double-trigger full acceleration within the CIC period plus salary/bonus severance could make finance leadership retention during M&A manageable; single-trigger acceleration applies if options are not assumed, which can influence transaction structuring considerations .
- Pay-for-performance linkage: Annual bonus tied to operational milestones and individual performance (both achieved at 100% for 2024), and the company emphasized cash/cash equivalents/marketable securities as the key pay-versus-performance measure, reflecting balance sheet strength as a core value driver in pre-revenue biotech .
- Ownership: Beneficial ownership is modest (<1%), with 102,867 options exercisable within 60 days as of March 31, 2025—monitor upcoming monthly vesting for potential incremental selling pressure, though 2024 activity was nil .